Availability of Therapies and Services for Parkinson's Disease in Africa: A Continent-Wide Survey.

BACKGROUND: The growing burden of Parkinson's disease (PD) in Africa necessitates the identification of available therapies and services to improve patient care. OBJECTIVE: To investigate the availability, affordability, frequency of usage, and insurance coverage of PD therapies (pharmacological, surgical, physical, and speech therapies) and services including specialized clinics, specialists, and nurses across Africa. METHODS: A comprehensive web-based survey was constructed and distributed to neurologists/physicians with a special interest in PD across Africa. The survey instrument includes components that address availability, affordability, frequency of use, and insurance coverage of different therapies and services. RESULTS: Responses were received from 28 (of 43 contacted) countries. Levodopa-based oral preparations were always available in 13 countries (46.4%) with variable affordability and "partial or no" insurance coverage in 60% of countries. Bromocriptine was the most available (50%) and affordable ergot dopamine agonists (DA), whereas non-ergot DA was always available in only six countries (21.4%). Trihexyphenidyl was the most available and affordable anticholinergic drug (46.4%). Tricyclic antidepressants and selective serotonin reuptake inhibitors were available in most countries (89.3% and 85.7% respectively), with variable affordability. Quetiapine and clozapine were less available. Specialized clinics and nurses were available in 25% and 7.1% of countries surveyed, respectively. Other services were largely unavailable in the countries surveyed. CONCLUSION: PD-specific therapies and services are largely unavailable and unaffordable in most African countries. The data provide a platform for organizing strategies to initiate or scale up existing services and drive policies aimed at improving access to care and tailoring education programs in Africa. © 2021 International Parkinson and Movement Disorder Society.

Compressions médullaires lentes : prévalence et étiologies, expérience du service de rhumatologie du CHU de Cocody à Abidjan

Objectif : Déterminer la prévalence du syndrome de compression médullaire lente et en identifier les étiologies en pratique rhumatologique à Abidjan.Patients et méthodes : Notre étude rétrospective et descriptive, a été menée au sein du service de rhumatologie du CHU de Cocody à Abidjan de Janvier 2004 à Décembre 2013. Nous avons sélectionné 121 patients souffrant de syndrome de compression médullaire clinique. Nous nous sommes intéressés aux données sociodémographiques et étiologiques.Résultats : La prévalence hospitalière était de 2,6% soit 121 patients sur 4531 pathologies rhumatologiques. Les hommes prédominaient (56,1%) avec un sex-ratio de 1,3. L'âge moyen était de 48,8 ans. Les patients se plaignaient d'un déficit moteur isolé (42,2%) ou associé à une cervicalgie (16,5%), à une dorsalgie (23,1%) et à une dorsolombalgie (18,2%). La durée moyenne d'évolution du syndrome de compression médullaire était de 1,2 mois. Les principaux signes cliniques étaient une parésie ou paralysie (98,3%) et une radiculalgie (93,4%). La tomodensitométrie constituait l'imagerie majeure (80,1%). Les étiologies étaient les spondylodiscites bactériennes (55,3%) dominées par le mal de Pott (52% des cas), les affections rachidiennes dégénératives (23,3% des cas) et les causes tumorales malignes (21,4%).Conclusion : Le syndrome de compression médullaire lente est rare en pratique rhumatologique à Abidjan. Les étiologies sont dominées par les spondylodiscites bactériennes principalement le mal de Pott

Symptomatic Moyamoya disease: clinical features and outcome after indirect bypass surgery in four French adults.

BACKGROUND: There are a few reports of moyamoya disease (MMD) in the European Caucasian adult population. We present the clinical manifestations, the neuroradiological aspects, the treatment, and the outcome after surgical revascularization of four French patients with MMD. PATIENTS AND METHODS: We identified four adults (age >18 years; three women and one man) with MMD who underwent digital subtraction catheter angiography at our institution from 1997 through 2006. The median age at symptom onset was 35 years (range, 22 to 41 years). The initial clinical presentation was intracerebral hemorrhage in three patients and ischemic stroke in one patient. RESULTS: Three patients underwent bilateral surgical revascularization and one patient underwent unilateral surgical revascularization. All patients underwent the same surgical revascularization procedure (encephalo-duro-arterio-myo-synangiosis). The mean (+/-SD) period of follow-up after diagnosis of MMD was 6 years and 9 months (+/-3 years and 5 months). No patient experienced any recurrent hemorrhagic or ischemic stroke. No perioperative stroke occurred. No patient was severely disabled or unable to walk. Three patients out of four were employed. CONCLUSION: Our data suggest safety and a potential benefit of surgical revascularization (indirect bypass surgery) in European adult patients with symptomatic MMD. Further long-term prospective multicenter studies are needed. The establishment of a registry would be useful in order to accumulate data in large numbers of European patients with this uncommon disease.